Intercept Pharmaceuticals Inc (NASDAQ:ICPT) finished Thursday with a subtraction of -$0.01 to close at $18.57, a downside of -0.05 percent. An average of 10,438,520 shares of common stock have been traded in the last five days. There was a gain of $7.77 in the past week, and it reached a new high 9 times over the past 12 months. The last 20 days have seen an average of 3,370,140 shares traded, while the 50-day average volume stands at 1,775,352.
ICPT stock has increased by 70.21% in the last month. The company shares reached their 1-month lowest point of $9.85 on 09/22/23. With the stock rallying to its 52-week high on 02/08/23, shares of the company touched a low of $8.82 and a high of $21.86 in 52 weeks. It has reached a new high 16 times so far this year and achieved 50.12% or $6.20 in price. In spite of this, the price is down -15.05% from the 52-week high.
Valuation Metrics
Intercept Pharmaceuticals Inc (ICPT) has a trailing price-to-earnings (P/E) ratio of 2.87. The stock’s beta is 0.95. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.53, the price-to-book (PB) ratio at 11.49.
Financial Health
The quick ratio of Intercept Pharmaceuticals Inc for the three months ended June 29 was 2.52, and the current ratio was 2.52, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 3.31 and a total debt to equity ratio of 4.94 for the quarter ending June 29. Its gross profit as reported stood at $284.73 million compared to revenue of $285.71 million.
Earnings Surprise
For the three-month period that ended June 29, Intercept Pharmaceuticals Inc had $223.6 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$5.86 million in the quarter, while revenues of -$32.14 million were shrunk -28.5%. The analyst consensus anticipated Intercept Pharmaceuticals Inc’s latest quarter earnings to come in at -$0.51 per share, but it turned out to be -$0.14, a 72.50% surprise. For the quarter, EBITDA amounted to -$8.98 million. Shareholders own equity worth $41.78 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Intercept Pharmaceuticals Inc (ICPT) price momentum. RSI 9-day as of the close on 28 September was 87.42%, suggesting the stock is Overbought, with historical volatility in this time frame at 294.44%.
As of today, ICPT’s price is $15.36 +71.94% or $7.77 from its 5-day moving average. ICPT is currently trading +70.05% higher than its 20-day SMA and +16.21% higher than its 100-day SMA. However, the stock’s current price level is +70.05% above the SMA50 and +26.33% above the SMA200.
The stochastic %K and %D were 98.73% and 74.99%, respectively, and the average true range (ATR) was 1.13. With the 14-day stochastic at 98.09% and the average true range at 0.95, the RSI (14) stands at 83.38%. The stock has reached 5.20 on the 9-day MACD Oscillator while the 14-day reading was at 5.85.
Analyst Ratings
H.C. Wainwright upgraded Intercept Pharmaceuticals Inc (NASDAQ: ICPT) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Sell.
